Enrolling by invitationPHASE1, PHASE2NCT04833907
rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease
Studying Canavan disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Myrtelle Inc.
- Principal Investigator
- Robert Lober, MD, PhDDayton Children's Hospital
- Intervention
- rAAV-Olig001-ASPA(drug)
- Enrollment
- 24 enrolled
- Eligibility
- All sexes
- Timeline
- 2021 – 2027
Study locations (1)
- Dayton Children's Hospital, Dayton, Ohio, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04833907 on ClinicalTrials.govOther trials for Canavan disease
Additional recruiting or active studies for the same condition.